EAST RUTHERFORD, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Cambrex
Corporation (NYSE: CBM) commented today on the impact of the recent
announcement regarding the status of Nabi Biopharmaceuticals' product
StaphVax(R).
(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )
"The recent announcement from Nabi Biopharmaceuticals does not impact our
2005 earnings guidance," commented John R. Leone, President and Chief
Executive Officer.
"We expect to provide 2006 guidance, as we normally do, during the fourth
quarter 2005 earnings announcement after we have completed the evaluation of
all of our prospects and opportunities within the Biopharma business and the
potential impact of this news."
Forward Looking Statement
This news release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under
The Securities Exchange Act of 1934, including, without limitation, statements
regarding expected performance, especially expectations with respect to sales,
research and development expenditures, earnings per share, capital
expenditures, acquisitions, divestitures, collaborations, or other expansion
opportunities. These statements may be identified by the fact that words such
as "expects," "anticipates," "intends," "estimates," "believes" or similar
expressions are used in connection with any discussion of future financial and
operating performance. The forward-looking statements contained herein are
based on current plans and expectations and involve risks and uncertainties
that could cause actual outcomes and results to differ materially from current
expectations including but not limited to, global economic trends,
pharmaceutical outsourcing trends, competitive pricing or product
developments, government legislation and/or regulations (particularly
environmental issues), tax rate, interest rate, technology, manufacturing and
legal issues, changes in foreign exchange rates, performance of minority
investments, un-collectable receivables, loss on disposition of assets,
cancellation or delays in renewal of contracts, and lack of suitable raw
materials or packaging materials. For further details and a discussion of
these and other risks and uncertainties, investors are cautioned to review the
Cambrex Annual Report on Form 10-K, including the Forward-Looking Statement
section therein, and other filings with the Securities and Exchange
Commission. The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.
About Cambrex Corporation
Cambrex is a global, diversified life sciences company dedicated to
providing products and services to accelerate and improve the discovery and
commercialization of human therapeutics. The Company employs approximately
1900 worldwide. For more information, please visit http://www.cambrex.com.
StaphVax(R) is a trademark of Nabi Biopharmaceuticals.
SOURCE Cambrex Corporation
 back to top
Related links:
http://www.cambrex.com
Company News On-Call:
http://www.prnewswire.com/comp/134219.html
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO
CONTACT:
Anne-Marie Hess, Director, Investor Relations
& Corporate Communications of Cambrex Corporation,
+1-201-804-3062, or annemarie.hess@cambrex.com
|
